{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:34Z","timestamp":1789477534422,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12519-026-01058-x","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:41:11Z","timestamp":1787409671000},"page":"741-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and molecular prognostic factors in newly diagnosed pediatric T-cell lymphoblastic lymphoma: a prospective, multicenter, single-arm phase 2 clinical trial"],"prefix":"10.1007","volume":"22","author":[{"given":"Xia","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-7562","authenticated-orcid":false,"given":"Chao-Ban","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Jia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Li","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Guo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjh.15793","volume":"185","author":"B Burkhardt","year":"2019","unstructured":"Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019;185:1158\u201370. https:\/\/doi.org\/10.1111\/bjh.15793.","journal-title":"Br J Haematol"},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","volume":"102","author":"E Landmann","year":"2017","unstructured":"Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102:2086\u201396. https:\/\/doi.org\/10.3324\/haematol.2015.139162.","journal-title":"Haematologica"},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol. 2009;27:3363\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.19.3367.","journal-title":"J Clin Oncol"},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puy\u00f3 P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144:2237\u201347. https:\/\/doi.org\/10.1182\/blood.2024024493.","journal-title":"Blood"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1182\/blood.V95.2.416","volume":"95","author":"A Reiter","year":"2000","unstructured":"Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416\u201321. https:\/\/doi.org\/10.1182\/blood.V95.2.416.","journal-title":"Blood"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ejca.2008.02.011","volume":"44","author":"A Uyttebroeck","year":"2008","unstructured":"Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44:840\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2008.02.011.","journal-title":"Eur J Cancer"},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2141.2008.07320.x","volume":"143","author":"M Abromowitch","year":"2008","unstructured":"Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children\u2019s Oncology Group. Br J Haematol. 2008;143:261\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07320.x.","journal-title":"Br J Haematol"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3760\/cma.j.issn.0578-1310.2015.12.013","volume":"53","author":"Lymphoma Study Group","year":"2015","unstructured":"Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association, Lymphoma Study Group Committee of Pediatrics Chinese Anti-Cancer Association. A collaborative study of children with lymphoblastic non-Hodgkin\u2019s lymphoma in China. Chin J Pediatr. 2015;53:931\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2015.12.013.","journal-title":"Chin J Pediatr"},{"key":"1058_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016503","author":"S Si Lim","year":"2023","unstructured":"Si Lim S, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023;141:3019\u201330. https:\/\/doi.org\/10.1182\/blood.2022016503.","journal-title":"Blood"},{"key":"1058_CR10","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/pbc.25607","volume":"62","author":"L Mussolin","year":"2015","unstructured":"Mussolin L, Buldini B, Lovisa F, Carraro E, Disar\u00f2 S, Nigro LL, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience. Pediatr Blood Cancer. 2015;62:1906\u201313. https:\/\/doi.org\/10.1002\/pbc.25607.","journal-title":"Pediatr Blood Cancer"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.20.00531","volume":"38","author":"RJ Hayashi","year":"2020","unstructured":"Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, et al. Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children\u2019s Oncology Group AALL0434. J Clin Oncol. 2020;38:3062\u201370. https:\/\/doi.org\/10.1200\/JCO.20.00531.","journal-title":"J Clin Oncol"},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood.2023021184","volume":"143","author":"RJ Hayashi","year":"2024","unstructured":"Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, et al. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children\u2019s Oncology Group trial AALL1231. Blood. 2024;143:2053\u20138. https:\/\/doi.org\/10.1182\/blood.2023021184.","journal-title":"Blood"},{"key":"1058_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094502","volume":"22","author":"MW Lato","year":"2021","unstructured":"Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M. The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2021;22:4502. https:\/\/doi.org\/10.3390\/ijms22094502.","journal-title":"Int J Mol Sci"},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/bloodadvances.2020001822","volume":"4","author":"E Kroeze","year":"2020","unstructured":"Kroeze E, Loeffen JLC, Poort VM, Meijerink JPP. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv. 2020;4:3466\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2020001822.","journal-title":"Blood Adv"},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","volume":"20","author":"C Graux","year":"2006","unstructured":"Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496\u2013510. https:\/\/doi.org\/10.1038\/sj.leu.2404302.","journal-title":"Leukemia"},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.2023022154","volume":"144","author":"E Balducci","year":"2024","unstructured":"Balducci E, Simonin M, Duployez N, Steiml\u00e9 T, Dourthe ME, Villarese P, et al. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. Blood. 2024;144:988\u20131000. https:\/\/doi.org\/10.1182\/blood.2023022154.","journal-title":"Blood"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","volume":"33","author":"A Rosolen","year":"2015","unstructured":"Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. 2015;33:2112\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.59.7203.","journal-title":"J Clin Oncol"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1200\/JCO.2006.06.2679","volume":"24","author":"A Schrauder","year":"2006","unstructured":"Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742\u20139. https:\/\/doi.org\/10.1200\/JCO.2006.06.2679.","journal-title":"J Clin Oncol"},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"A M\u00f6ricke","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D\u00f6rdelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477\u201389. https:\/\/doi.org\/10.1182\/blood-2007-09-112920.","journal-title":"Blood"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood.V100.2.420","volume":"100","author":"M Arico\u0300","year":"2002","unstructured":"Arico\u0300 M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420\u20136. https:\/\/doi.org\/10.1182\/blood.V100.2.420.","journal-title":"Blood"},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.2014.59.0745","volume":"33","author":"JT Sandlund","year":"2015","unstructured":"Sandlund JT, Guillerman RP, Perkins SL, Pinkerton CR, Rosolen A, Patte C, et al. International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol. 2015;33:2106\u201311. https:\/\/doi.org\/10.1200\/JCO.2014.59.0745.","journal-title":"J Clin Oncol"},{"key":"1058_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE\u2013version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2021;112:90\u20132. https:\/\/doi.org\/10.1016\/j.adengl.2019.05.021.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38:3282\u201393. https:\/\/doi.org\/10.1200\/JCO.20.00256.","journal-title":"J Clin Oncol"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","volume":"32","author":"J Stary","year":"2014","unstructured":"Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32:174\u201384. https:\/\/doi.org\/10.1200\/JCO.2013.48.6522.","journal-title":"J Clin Oncol"},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","volume":"118","author":"Y Matloub","year":"2011","unstructured":"Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2011;118:243\u201351. https:\/\/doi.org\/10.1182\/blood-2010-12-322909.","journal-title":"Blood"},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood.2024025307","volume":"144","author":"M Vrugt","year":"2024","unstructured":"Vrugt M, Wessolowski J, Randau G, Alfert A, Mueller S, Scholten K, et al. Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB:: NOTCH1 fusions with unfavorable outcome. Blood. 2024;144:1412\u20137. https:\/\/doi.org\/10.1182\/blood.2024025307.","journal-title":"Blood"},{"key":"1058_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.117","volume":"8","author":"E Kroeze","year":"2024","unstructured":"Kroeze E, Kleisman MM, Kester LA, Scheijde-Vermeulen MA, Sonneveld E, Buijs-Gladdines JGC, et al. NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker. HemaSphere. 2024;8:e117. https:\/\/doi.org\/10.1002\/hem3.117.","journal-title":"HemaSphere"},{"key":"1058_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2015.203","volume":"30","author":"ST Balbach","year":"2016","unstructured":"Balbach ST, Makarova O, Bonn BR, Zimmermann M, Rohde M, Oschlies I, et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2016;30:970\u20133. https:\/\/doi.org\/10.1038\/leu.2015.203.","journal-title":"Leukemia"},{"key":"1058_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29926","volume":"69","author":"J Salmer\u00f3n-Villalobos","year":"2022","unstructured":"Salmer\u00f3n-Villalobos J, Ramis-Zaldivar JE, Balagu\u00e9 O, Verd\u00fa-Amor\u00f3s J, Celis V, S\u00e1bado C, et al. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2022;69:e29926. https:\/\/doi.org\/10.1002\/pbc.29926.","journal-title":"Pediatr Blood Cancer"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01058-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01058-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01058-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:21:02Z","timestamp":1789474862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01058-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01058-x","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict with this topic or these data. No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CCCG\u2013LBL-2016 is an investigator-initiated, multicenter, open-label, phase 2 clinical trial conducted across seven pediatric oncology centers in China (ClinicalTrials.gov identifier: NCT02845882). The study protocol, in compliance with the principles of the Declaration of Helsinki, was approved by the principal institutional ethics committee of Shanghai Children's Medical Center (SCMCIRB-J2016001). Written informed consent was obtained from parents or legal guardians of all participants.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}